World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 19 March 2012
Main ID:  EUCTR2004-001876-37-DE
Date of registration: 27/02/2007
Prospective Registration: Yes
Primary sponsor: Academic Medical Centre
Public title: BENEFIT-study: A randomized placebo controlled trial of anti-TNF-alpha chimeric monoclonal antibody ( infliximab) in idiopathic pulmonary fibrosis. - BENEFIT
Scientific title: BENEFIT-study: A randomized placebo controlled trial of anti-TNF-alpha chimeric monoclonal antibody ( infliximab) in idiopathic pulmonary fibrosis. - BENEFIT
Date of first enrolment: 27/07/2007
Target sample size: 18
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001876-37
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no  
Phase: 
Countries of recruitment
Germany
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
Patients to be included must meet the following criteria:

1. Diagnosis of IPF(2):
a) If possible a thoracoscopic or open lung biopsy showing UIP. A thoracoscopic or open lung biopsy must be performed in patients <51 years old. Transbronchial biopsy is strongly advocated and should show no features to support an alternate diagnosis.
b) Insidious onset of otherwise unexplained dyspnea on exertion.
c) Presence of bibasilar, inspiratory crackles.
d) Abnormal lung function: VC £ 80% predicted or TLC < 90% predicted, plus DLco < 80% predicted.
e) Parenchymal abnormalities on chest X-ray.
f) HRCT: bilateral parenchymal abnormalities with peripheral and bibasilar distribution showing linear and reticular opacities, usual in conjunction with subpleural honeycombing and architectural distortion.
g) Exclusion of other forms of interstitial lung diseases.
h) In patients > 50 years fulfilling all above mentioned criteria a BAL to exclude other causes of interstitial lung disease is sufficient and a lung biopsy is not necessary.

2. Show stable disease or failure to respond to standard medication (i.e. azathioprine and prednisolone) (as defined by the ATS/ERS criteria(2)) during a minimum of 3 months prior to the study, with a minimum dose of prednisolone (or equivalent) of 20 mg daily, and azathioprine 2 mg per kg with a maximum of 200 mg daily during 3 months.

3. Men and women between 40 and up until 79 years.

4. Disease duration between 3 months and 2 years.

5. Men and women must use adequate birth control measures (eg, abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) for the duration of the study and should continue such precautions for 6 months after receiving the last infusion.

6. The screening laboratory test results must meet the following criteria:
a. Haemoglobin ³ 8.5 g/dL (5.3 mmol/L)
b. WBC ³ 3.5 x 109/L
c. Neutrophils ³ 1.5 x 109/L
d. Platelets ³ 100 x 1012/L
e. SGOT (AST) and alkaline phosphatase levels must be within 3 times the upper limit of normal range for the laboratory conducting the test.

7. Patient must be able to adhere to the study visit schedule and other protocol requirements.

8. Patient must be able to communicate meaningfully with the study personnel.

9. The patient must be capable of giving informed consent and the consent must be obtained prior to any screening procedures.

10. Must have a chest radiograph within 3 months prior to first infusion with no evidence of malignancy or infection.

11. Are considered eligible according to the tuberculosis (TB) eligibility assessment, screening, and early detection of reactivation rules as decribed in section 4.3.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Patients will be excluded from this study for any of the following reasons:

1. Critical low lung function: FVC < 50%.

2. Artificially ventilated.

3. Inability to undergo a broncho-alveolar lavage.

4. Patients that were treated with IFN-?.

5. Women who are pregnant, nursing, or planning pregnancy within 1,5 years after screening (ie, approximately 6 months following last infusion).

6. Use of any investigational drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer.

7. Treatment with any other therapeutic agent targeted at reducing TNF (eg, pentoxifylline, thalidomide, etanercept, adalimumab etc.) within 3 months of screening.

8. Previous administration of infliximab.

9. History of receiving human/murine recombinant products or known allergy to murine products.

10. Serious infections (such as pneumonia or pyelonephritis) in the previous 3 months. Less serious infections (such as acute upper respiratory tract infection [colds] or simple urinary tract infection) need not be considered exclusions at the discretion of the investigator.

11. Documented HIV infection.

12. Active hepatitis- B or hepatitis-C.

13. Are considered ineligible according to the TB eligibility assessment, screening, and early detection of reactivation rules defined in Section 4.3.

14. Have or have had an opportunistic infection (eg, herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening..

15. Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, cardiac, neurologic, or cerebral disease (including demyelinating diseases such as multiple sclerosis).

16. Concomitant congestive heart failure and/or cor pulmonale, including medically controlled asymptomatic patients. Criteria for cor pulmonale are based on cardiac sonography: estimated systolic pulmonary artery pressure = 40 mmHg at rest.

17. Presence of a transplanted organ (with the exception of a corneal transplant > 3 months prior to screening).

18. Malignancy within the past 5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence).

19. History of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as nodes in the posterior triangle of the neck, infra-clavicular, epitrochlear, or periaortic areas), or splenomegaly.

20. Known recent substance abuse (drug or alcohol).

21. Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period.

22. Have a chest radiograph at screening that shows evidence of malignancy, infection, or any abnormalities suggestive of TB as described in Section 4.3.2.1




Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Idiopathic Pulmonary Fibrosis
MedDRA version: 9.1 Level: LLT Classification code 10021240 Term: Idiopathic pulmonary fibrosis
Intervention(s)

Trade Name: Remicade
Product Name: Remicade
Pharmaceutical Form: Powder for solution for infusion
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use

Primary Outcome(s)
Secondary Objective: * Has a potential beneficial effect on disease progression.
* Is tolerable and safe.
Main Objective: The objectives of the study are to establish that the administration of monoclonal antibody anti-TNF-alpha in patients with IPF:
* Affects inflammatory and pro-fibrotic cytokine expression in broncho-alveolar lavage and blood.
Primary end point(s): -Change in FVC from baseline.
-Time to disease progression (ATS criteria)(2).
Secondary Outcome(s)
Secondary ID(s)
CO168X71 (EU-0037)
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history